Intended for healthcare professionals

News

Seven days in medicine: 15-21 May 2024

BMJ 2024; 385 doi: https://doi.org/10.1136/bmj.q1130 (Published 23 May 2024) Cite this as: BMJ 2024;385:q1130

Mental health

MPs call for radical change to end over-reliance on pills

A group of MPs has called for a radical overhaul of the way poor mental health is managed in the UK, to move away from “over-reliance on psychiatric drugs.” The Beyond Pills All Party Parliamentary Group said that a paradigm shift was needed away from “the traditional biomedical model” towards a more holistic approach to tackle the social, economic, and psychological determinants of mental health. The group’s report1 highlighted the mental health impact of toxic relationships, abuse, and violence, as well as the role of wider societal factors such as economic insecurity, poverty, poor housing, inadequate nutrition, and damaged communities. (Full story doi:10.1136/bmj.q1095)

Semaglutide

Drug maker’s study points to sustained weight loss

A new analysis of data from Novo Nordisk’s Select trial indicated that semaglutide (marketed as Wegovy) can enable patients who are overweight or obese to “achieve clinically meaningful weight loss” for at least four years, with fewer serious adverse events than placebo.2 The analysis, conducted by the manufacturer and published in Nature Medicine, examined the weight loss effects of semaglutide across a geographically and ethnically diverse population for four years. It reported improvements in men and women and in all ethnic and age categories studied, irrespective of starting body size. (Full story doi:10.1136/bmj.q1113)

Naloxone

Plans for increased access are “turning point”

The …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription